Cymabay Therapeutics (CBAY) 5.00 $CBAY CymaBay product

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cymabay Therapeutics (CBAY) 5.00 $CBAY

CymaBay product candidate an Orphan Drug for severe hypertriglyceridemia
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 8:34AM CDT

CBAY: 5.00 (-0.14)

CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia
Marketwired - Wed Apr 22, 7:02AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for MBX-8025 to treat patients with hyperlipoproteinemia types I or V (Fredrickson classification). MBX-8025 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist being evaluated by CymaBay in high unmet need and orphan diseases. Recently, the FDA also granted orphan drug designation for MBX-8025 to treat patients with homozygous familial hypercholesterolemia (HoFH).
CBAY: 5.00 (-0.14)

CymaBay Therapeutics Strengthens Management Team With the Appointment of Kirk Rosemark to VP, Regulatory Affairs and Quality Assurance
Marketwired - Mon Apr 20, 7:02AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced the appointment of Kirk Rosemark to Vice President of Regulatory Affairs and Quality Assurance, effective April 27, 2015. Mr. Rosemark will report directly to Harold Van Wart, CymaBay's Chief Executive Officer.
CBAY: 5.00 (-0.14)

CymaBay to Present at the 14th Annual Needham Healthcare Conference
Marketwired - Tue Apr 07, 6:00AM CDT
CymaBay Therapeutics Inc. (NASDAQ: CBAY) announced today that Harold Van Wart, Ph.D., President and Chief Executive Officer, will present a corporate update at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, at 12:10 p.m. ET at the Westin Grand Central Hotel in New York City.
CBAY: 5.00 (-0.14)

CymaBay's MBX-8025 an Orphan Drug for genetic hypercholesterolemia
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 9:00AM CDT

CBAY: 5.00 (-0.14)

CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia
Marketwired - Wed Mar 25, 7:02AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for MBX-8025 as a treatment for homozygous familial hypercholesterolemia (HoFH). MBX-8025 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist being evaluated in high unmet need and orphan diseases.
CBAY: 5.00 (-0.14)

CymaBay Therapeutics Appoints Robert J. Wills, Ph.D. to Board of Directors
Marketwired - Tue Mar 24, 7:02AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced the appointment of Robert J. Wills, Ph.D., to the Company's Board of Directors.
CBAY: 5.00 (-0.14)

CymaBay Therapeutics to Host Key Opinion Leader Meeting on March 27 in New York City
Marketwired - Mon Mar 23, 9:01AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that it will host a Key Opinion Leader breakfast focused on gout, current treatment options and the company's Phase 2 drug candidate arhalofenate. The event and live webcast will take place on Friday, March 27 from 8:00 am-9:30 am Eastern Time in New York City.
CBAY: 5.00 (-0.14)

CymaBay Therapeutics' (CBAY) CEO Harold Van Wart on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 18, 9:34PM CDT

CBAY: 5.00 (-0.14)

CymaBay Therapeutics EPS of -$0.87
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 3:21PM CDT

CBAY: 5.00 (-0.14)

CymaBay Reports Fourth Quarter and Full Year 2014 Financial Results
Marketwired - Wed Mar 18, 3:01PM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders, today provided recent corporate highlights and announced financial results for the quarter and year ended December 31, 2014.
CBAY: 5.00 (-0.14)

CymaBay Therapeutics to Announce Fourth Quarter and Year-End 2014 Financial Results and Business Update on Wednesday, March 18, 2015
Marketwired - Wed Mar 11, 7:02AM CDT
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that it will host a conference call and live audio webcast on Wednesday, March 18 at 4:15 p.m. Eastern Time (1:15 p.m. Pacific Time) to discuss the Company's financial results for the quarter and year ended December 31, 2014 and to provide a general business update.
CBAY: 5.00 (-0.14)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 193

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Mudrick Urges Doncasters to Test a Strategic Sale Now

Updated Category News Views 0

Castings are rarely glamorous until nobody can get them, and Mudrick Capital is betting that ugly little industrial reality could make Doncasters worth far more in a takeover than the market currently credits. The event-driven investor, which says it owns roughly 4.3% of DPC Holdings Limited, has asked the board to quietly evaluate strategic alternatives, including a sale...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 125

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 102

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 67

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 48

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 55

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 131

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading

Top 5 Most Recently Viewed Articles

BioMarin's Strong 2024 Performance Fuels 2025 Expectations

Updated Category News Views 392

BioMarin's Empowering Growth Journey Into 2025 BioMarin Pharmaceutical Inc. has marked a significant achievement with its record performance in 2024, setting a strong foundation for the upcoming year. The company demonstrated robust operational execution and is gearing up for a year of potential double-digit revenue growth as it advances its corporate strategy focusing on...

Continue Reading
Berkshire Hills Bancorp Declares Cash Dividend for Shareholders

Updated Category News Views 104

Berkshire Hills Bancorp Announces Quarterly Dividend Berkshire Hills Bancorp, Inc. (NYSE: BHLB) has recently declared a quarterly cash dividend of $0.18 per common share for its shareholders. This decision by the Board of Directors aims to reward shareholders who are on record by a specified date. Details of the Dividend Announcement The approved cash dividend will be...

Continue Reading
Maiden United Transforms Adele's Skyfall into Heavy Metal Epic

Updated Category News Views 167

Maiden United Transforms Iconic Adele Song into Heavy Metal What if Iron Maiden had recorded the legendary James Bond theme song? Maiden United, a notable tribute band dedicated to Iron Maiden, has taken that intriguing concept and turned it into reality. The band has just unveiled their latest EP entitled Agent 666, which features an electrifying heavy metal cover of...

Continue Reading
Cherokee Federal Boosts Growth with MSI, LLC Investment

Updated Category News Views 213

Cherokee Federal Expands Presence Through Strategic Investment Cherokee Federal, a division of Cherokee Nation Businesses (CNB), has recently announced a significant move in the federal contracting realm. They have acquired a majority stake in Management Science and Innovation, LLC, also known as MSI. This strategic investment marks another milestone under their...

Continue Reading
Metallurgical Coal Market Expected Growth Amid Steel Demand Spike

Updated Category News Views 125

Growth of the Metallurgical Coal Market The global metallurgical coal market is poised for significant growth, estimated at USD 95.27 billion from 2024 to 2028. This growth is largely driven by the increasing demand for steel, which is essential for numerous infrastructure projects around the world. As smart city developments surge, the necessity for high-quality steel...

Continue Reading